Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year

The Cambridge, Massachusetts-based company said preliminary Elevidys net product revenue is expected to be $131.3 million for Q4 and $200.4 million for FY23, significantly exceeding consensus. Fourth quarter and full-year 2023 net product revenue for Sarepta's RNA-based PMOs are expected to be…#cambridge #massachusetts #sarepta #wedbush #dmd #fda #elevidysdmd #srpt #boeing #max
Source: Reuters: Health - Category: Consumer Health News Source Type: news